Minaris Beyond the RFP: Key Selection Criteria For Cell & Gene Therapy CDMOs

Selecting the right manufacturing partner is a pivotal decision in the development of cell and gene therapies, where scientific complexity and unpredictable program trajectories demand more than transactional engagement. A strong partnership begins with a clear internal assessment of program goals, future needs, and operational constraints. Sponsors are encouraged to evaluate potential partners through three core lenses: technical capability, operational agility, and project advocacy—each of which influences long‑term success as requirements evolve.

Beyond initial criteria, meaningful alignment depends on transparency from both sides. Sponsors should openly communicate resource limitations, risks, and milestone pressures, while a mature CDMO demonstrates proactive honesty by challenging assumptions and refining proposals. Evaluating deeper strategic signals—such as investment in future technologies, global regulatory readiness, and cost‑of‑goods awareness—helps distinguish true partners from surface‑level responders.

Ultimately, success emerges when both organizations operate as one unit, sharing responsibility, culture, and long‑term vision to advance impactful therapies.